963-RAS-GTP Inhibition in KRAS Mutant Cholangiocarcinoma

This study examines the therapeutic efficacy of RAS(ON) multi-selective inhibitors—specifically daraxonrasib and the compound RMC-7977—in treating KRAS-mutant cholangiocarcinoma (CCA). Through extensive testing in cell-derived and patient-derived models, researchers demonstrated that these inhibitors significantly suppress tumor growth and improve survival rates by targeting the active, GTP-bound ...去小宇宙查看完整单集简介
前往小宇宙评论区与主播互动